The 22-Modifier in Total Hip and Knee Arthroplasty: A Comprehensive Analysis

Robert Comrie,Allyson N. Pfeil,Pito Huerta,Kurt Lautenshlager,Corey F. Hryc,Ugonna N. Ihekweazu
DOI: https://doi.org/10.1016/j.arth.2024.01.046
IF: 4.435
2024-02-04
The Journal of Arthroplasty
Abstract:Background The 22-Modifier requests additional compensation for increased case complexity. Unfortunately, there is little to guide physicians on the application, which may increase successful reimbursement. We sought to evaluate various factors affecting reimbursement of the 22-modifier in primary total joint arthroplasty and report which factors contributed to successful utilization. Methods In this retrospective study, all cases from a single practice where the 22-modifier was added to 27130 (THA) and 27447 (TKA) from October 2018 to March 2022 were evaluated. Out of 6,869 total cases performed, 816 22-modifier cases were identified (11.9%). Operative reports, demographics, insurance type, billing information, and clinical records were assessed. T -tests were used to determine statistical significance. Results Of 816 cases, 221 (27.1%) were successfully reimbursed. Cases justified 22-modifier application with obesity, anatomic variations, or intraoperative factors. Some cases lacked justification, or operative reports were not submitted. Reimbursement was successful for 27.6% of obesity cases, 29.7% of intraoperative complications, and 35.7% of anatomic variations. There was a significantly higher likelihood of Medicare reimbursement than third-party payers or Medicaid (69.6 versus 20.5 and 6.9%) ( P < 0.0001). Additionally, Medicare was more likely to reimburse for obesity (76.6 versus 20.0, and 5.2%), anatomic variations (77.3 versus 22.0%), and intraoperative factors (66.6 versus 21.1, and 1.7%). Conclusion Reimbursement for 22-modifier cases in total joint arthroplasty (TJA) is unlikely. Obesity was cited for most 22-modifier justifications, but anatomic variation justification was successfully reimbursed most often. Medicare was most likely to reimburse compared to third-party payers or Medicaid. These findings should be considered when applying a 22-modifier to TJA procedures.
orthopedics
What problem does this paper attempt to address?